A Real-World Assessment of Hepatic Dysfunction Among Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Receiving First-Line (1L) Tyrosine Kinase Inhibitors (TKIs) in the United States

被引：0
|
作者：
Kolibaba, Kathryn
Zhou, Jie
Keating, Scott Justin
Clark, Jamyia
Brokars, John
Kee, Arianna
Copher, Ronda
Stwalley, Brian
Jabbour, Elias
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Real-World Effectiveness of First-Line (1L) Dasatinib Versus 1L Imatinib in Newly Diagnosed Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML)
    Klink, Andrew J.
    Keating, Scott Justin
    Brokars, John
    Kee, Arianna
    Copher, Ronda
    Stwalley, Brian
    Feinberg, Bruce
    Jabbour, Elias
    BLOOD, 2020, 136
  • [2] Real-World Treatment Patterns Among Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Cycling Through Multiple Tyrosine Kinase Inhibitors (TKIs) in the United States (US)
    Kota, Vamsi
    Maegawa, Rodrigo
    Latremouille-Viau, Dominick
    Jadhav, Kejal
    Rossi, Carmine
    Guerin, Annie
    Iorga, Serban
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S300 - S301
  • [3] Incidence of Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated with First-Line (1L) Tyrosine Kinase Inhibitors (TKI) in SIMPLICITY: An Observational Study
    Goldberg, Stuart L.
    Mauro, Michael
    Cortes, Jorge
    Keating, Scott J.
    Bhandari, Hitesh
    Chen, Clara
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S241 - S242
  • [4] Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US
    Mauro, Michael J.
    McGarry, Lisa J.
    Lustgarten, Stephanie
    Huang, Hui
    BLOOD, 2016, 128 (22)
  • [5] Outcomes of Chronic Phase Chronic Myeloid Leukemia (CP-CML) after Sequential Treatment with Tyrosine Kinase Inhibitors (TKI)
    Kong, Jee Hyun
    Winton, Elliott F.
    Heffner, Leonard
    Gaddh, Manila
    Hill, Brittany
    Arellano, Martha L.
    El-Rassi, Fuad
    Kim, Audrey
    Kota, Vamsi
    BLOOD, 2017, 130
  • [6] Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)
    Mato, Anthony R.
    Ravelo, Arliene
    MyTo, Tu
    Schuldt, Robert
    Biondo, Juliana M. L.
    BLOOD, 2021, 138
  • [7] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [8] Echocardiographic Findings in Patients (pts) Receiving Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Chronic Myeloid Leukemia (CML)
    Gurguis, Christopher
    de Armas, Lizette Rodriguez
    Kantarjian, Hagop M.
    Boddu, Prajwal C.
    Jain, Preetesh
    Borthakur, Gautam
    Giza, Dana Elena
    Iliescu, Gloria
    Lopez-Mattei, Juan
    Kim, Peter
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Wierda, William G.
    Kornblau, Steven
    Jabbour, Elias J.
    Iliescu, Cezar
    Cortes, Jorge E.
    BLOOD, 2017, 130
  • [9] REAL-WORLD TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) IN PATIENTS WHO FAILED ≥2 PRIOR TYROSINE KINASE INHIBITORS (TKIS) AMONG US COMMUNITY ONCOLOGISTS
    Feinberg, B.
    Kish, J.
    Laney, J.
    Mujumdar, U.
    McGarry, L.
    Huang, H.
    HAEMATOLOGICA, 2016, 101 : 737 - 738
  • [10] Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia
    Szeto, Andy H.
    Bucci, Tyler
    Deal, Allison
    Zhu, Anqi
    Ahmad, Majd
    Cass, Amanda S.
    Sketch, Margaret R.
    Kemper, Ryan
    Zeidner, Joshua F.
    Foster, Matthew C.
    Muluneh, Benyam
    Crona, Daniel J.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (07) : 753 - 763
12345